Most Read Articles
4 days ago
Routinely used for treating cardiovascular diseases, statins have been shown to benefit other conditions, and new evidence suggests that using the drug at high intensity reduces the risk of hip or knee replacement, an effect that may be specific to rheumatoid arthritis.
Jairia Dela Cruz, 5 days ago
Following vegan and vegetarian diets, which offer plenty of what is good for health, has been reported to have a downside: an increased risk of depression and anxiety, especially for younger adults.
Pearl Toh, 29 Jun 2020
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
Roshini Claire Anthony, 2 days ago

Upadacitinib may be a suitable treatment for patients with active psoriatic arthritis (PsA) who have insufficient response to non-biologic disease-modifying anti-rheumatic drugs (non-bDMARDs), according to results of the phase III SELECT-PsA-1* trial presented at EULAR 2020.

Dupilumab improves symptoms, quality of life of patients with chronic nodular prurigo

19 Jun 2020

Use of dupilumab helps reduce itch and improve chronic nodular prurigo (CNPG) skin lesions, a recent study has shown.

“CNPG is a multifactorial skin disease characterized by itchy papules and nodules, usually resistant to standard treatment and associated with markedly impaired quality of life,” the author said.

This retrospective, multicentre study was conducted to assess the effectiveness and tolerability of dupilumab in treating adult patients with CNPG refractory to both topical and systemic therapies. Participants received dupilumab for at least 16 weeks.

Twenty-seven patients with CNPG achieved clinical improvement in terms of itch, skin lesions, sleeplessness, and quality of life. Of the participants, 24 (88.9 percent) had at least 16-week continuous treatment, and 11 of these patients (45.8 percent) had Investigator Global Assessment (IGA) score 1. Nineteen of 24 patients (79.2 percent) achieved at least a 2-grade reduction in IGA score.

At week 16, numeric rating scale values decreased from 8.9 to 2.7 for itch and from 8.2 to 1.7 for sleeplessness (p<0.001). Furthermore, 10 patients achieved 36 weeks of continuous treatment while maintaining clinical efficacy.

The study had several limitations, including a lack of validated assessment tools at the initial data collection, a limited cohort of treated patients, and a short-term observation period.

A recent study also reported the beneficial effects of dupilumab in patients with bullous pemphigoid, resulting in disease clearance or satisfactory response in several patients. [J Am Acad Dermatol 2020;83:46-52]

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
4 days ago
Routinely used for treating cardiovascular diseases, statins have been shown to benefit other conditions, and new evidence suggests that using the drug at high intensity reduces the risk of hip or knee replacement, an effect that may be specific to rheumatoid arthritis.
Jairia Dela Cruz, 5 days ago
Following vegan and vegetarian diets, which offer plenty of what is good for health, has been reported to have a downside: an increased risk of depression and anxiety, especially for younger adults.
Pearl Toh, 29 Jun 2020
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
Roshini Claire Anthony, 2 days ago

Upadacitinib may be a suitable treatment for patients with active psoriatic arthritis (PsA) who have insufficient response to non-biologic disease-modifying anti-rheumatic drugs (non-bDMARDs), according to results of the phase III SELECT-PsA-1* trial presented at EULAR 2020.